NICE Rejects Roche’s Avastin For Ovarian Cancer Due To Excessive Cost
This article was originally published in The Pink Sheet Daily
Roche’s extremely high price for Avastin results in yet another knock-back by Britain’s NICE, this time for advanced ovarian cancer.
You may also be interested in...
The U.K.’s cost watchdog NICE has waved through Novartis’ Lucentis for macular edema after the Swiss manufacturer offered a discount.
The U.K.'s health care cost regulator says it wouldn't recommend Roche's Avastin as a first-line treatment for advanced ovarian cancer along with standard chemotherapy, on grounds it doesn’t offer value for money.
The United Kingdom is creating a £600 million Cancer Drugs Fund to improve treatment access but a consultation document on the initiative is doing little to ease concerns about regional disparities in care.